Clinical Trial Update: A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE) [Phase 1, Phase 2]

View source ↗

Summary

Lyell Immunopharma's IMPT-514 trial in active refractory lupus nephritis and systemic lupus erythematosus has been withdrawn (Phase 1/Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lupus Nephritis
• Systemic Lupus Erythematosus

Drugs mentioned

• IMPT-514

Snippet

Sponsor: Lyell Immunopharma, Inc. | Conditions: Systemic Lupus Erythematosus, Lupus Nephritis | Phase 1, Phase 2 | Status: WITHDRAWN